Otsuka Dermatitis Candidate Looks Good At Phase III

New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.

Dermatitis
Progress For New Dermatitis Option • Source: Shutterstock

Otsuka Pharmaceutical Co. Ltd.’s topical candidate for atopic dermatitis (AD) has met its endpoints in a Japanese Phase III program, setting the stage for an approval filing in this potentially large market.

Two double-blind, parallel-group studies with the phosphodiesterase 4 (PDE4) inhibitor difamilast (OPA-15406) in both adult and pediatric patients assessed 1%...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia